GRAIL

Dana-Farber Cancer Institute is a prominent comprehensive cancer center located in Boston, Massachusetts. Founded in 1947 by Dr. Sidney Farber, it initially focused on pediatric leukemia and has since expanded to provide care for patients of all ages. The institute is a principal teaching affiliate of Harvard Medical School and is recognized as one of the top cancer hospitals in the U.S., designated as a National Cancer Institute comprehensive cancer center. Dana-Farber offers a wide range of cancer care services, including clinical treatment, research, nutrition, social work, and counseling. It specializes in various cancers, including breast, gastrointestinal, and neuro-oncology, and is known for its extensive Pediatric Brain Tumor Program and the nation's oldest bone marrow transplantation program. The institute collaborates closely with Boston Children's Hospital and other medical centers to enhance patient care and advance research in areas such as genetics, immunotherapy, and personalized medicine.

Mayo Clinic is a nonprofit organization committed to clinical practice, education, and research, providing whole-person care and solving complex medical challenges for patients from around the world.

AstraZeneca is a global pharmaceutical company focused on the research, development, and commercialization of prescription medicines. With around 90,000 employees in 85 countries, the company aims to harness scientific advancements for the benefit of people and society. AstraZeneca operates in various functions, including Clinical Development, Regulatory Affairs, Finance, IT, and Manufacturing. The company specializes in three main therapeutic areas: oncology, respiratory, and immunology. In oncology, AstraZeneca is dedicated to developing innovative treatments that aim to redefine cancer care. In the respiratory and immunology sectors, the company works to improve outcomes for patients with asthma and COPD, as well as other immune-driven diseases. Additionally, AstraZeneca has expanded its focus on rare diseases through its acquisition of Alexion, enhancing its capabilities in this area. The company is committed to advancing science and creating impactful therapies across multiple health conditions.